Friday, July 10, 2026

pharma · Recurrent Respiratory Tract Infections · Actinic Keratosis on the Face or Scalp

ALMIRALL S.P.A

ALMIRALL S.P.A is a pharma organization headquartered in Barcelona, IT. Primary therapeutic focus areas include Recurrent Respiratory Tract Infections, Actinic Keratosis on the Face or Scalp, Alopecia areata, Actinic Ker

VIA MESSINA 38, MILANO, Mi 20154, IT, Barcelona HQ
2 Employees
NMPA registrant Type
Company details
Status
Public
HQ
VIA MESSINA 38, MILANO, Mi 20154, IT, Barcelona
Employees
2
Programs
11
Drugs
20
Patents
308
Clinical program

LAD328, SODIUM CHLORIDE

Phase 2 · small molecule · moderate-to-severe hidradenitis suppurativa

LAD328, SODIUM CHLORIDE for moderate-to-severe hidradenitis suppurativa is a Phase 2 program (small_molecule) at Almirall, S.A. with 1 ClinicalTrials.gov record(s).

← All Almirall, S.A. projects Phase 2 small molecule active

Internal code M-00401-10

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Almirall, S.A.
Phase
Phase 2
Modality
small_molecule
Indication
moderate-to-severe hidradenitis suppurativa
Status
active
Trials
1